Biopharma industry confidence at highest in years despite geopolitical headwinds

GlobalData says that the industry has “absorbed significant disruption”, with high M&A levels testament to recovery. GlobalData says that the industry has “absorbed significant disruption”, with high M&A levels testament to recovery. GlobalData’s State of the Biopharmaceutical Industry 2026 (Mid-Year Update) found that 55% of respondents felt optimistic or very optimistic about industry growth over the next 12 months. Credit: LvNL/Shutterstock.com. Biopharma executives’ confidence in the industry has reached its highest point in four years, reflecting a successful navigation through a largely disrupted geopolitical landscape. GlobalData’s State of the Biopharmaceutical Industry 2026 (Mid-Year Update) , which surveyed 157 pharmaceutical professionals,…

Source: Clinical Trials Arena